Guggenheim Lowers argenex (NASDAQ:ARGX) Price Target to $1,120.00

argenex (NASDAQ:ARGX) had its target price reduced by Guggenheim from $1,160.00 to $1,120.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s target price suggests a potential upside of 46.04% from the company’s previous close.

ARGX has been the topic of several other reports. Wedbush reiterated an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research note on Wednesday, January 14th. Piper Sandler upped their target price on shares of argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. HC Wainwright lifted their price target on shares of argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. DZ Bank raised shares of argenex to a “strong-buy” rating in a research report on Friday, December 19th. Finally, Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, argenex has an average rating of “Moderate Buy” and a consensus target price of $999.22.

argenex Price Performance

Shares of NASDAQ ARGX opened at $766.92 on Friday. The business has a 50-day moving average of $826.36 and a two-hundred day moving average of $811.97. The company has a market capitalization of $47.46 billion, a price-to-earnings ratio of 39.29, a price-to-earnings-growth ratio of 0.67 and a beta of 0.37. argenex has a 1 year low of $510.05 and a 1 year high of $934.62.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 26th. The company reported $8.02 EPS for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. argenex had a return on equity of 63.59% and a net margin of 30.42%. As a group, equities research analysts expect that argenex will post 3.13 earnings per share for the current year.

Institutional Investors Weigh In On argenex

A number of institutional investors and hedge funds have recently made changes to their positions in ARGX. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of argenex by 91.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock worth $6,511,000 after purchasing an additional 4,217 shares during the period. Allianz Asset Management GmbH increased its stake in argenex by 21.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock valued at $2,708,000 after buying an additional 645 shares during the period. Allspring Global Investments Holdings LLC increased its stake in argenex by 14.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock valued at $162,160,000 after buying an additional 26,343 shares during the period. Alta Wealth Advisors LLC purchased a new position in argenex during the 3rd quarter worth $623,000. Finally, Fiera Capital Corp lifted its stake in shares of argenex by 12.1% in the 3rd quarter. Fiera Capital Corp now owns 177,654 shares of the company’s stock worth $131,030,000 after acquiring an additional 19,180 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.